University of California

Cedars-Sinai Medical Center

The United States Government as Represented by the Department of Veterans Affairs

Memorial Sloan Kettering Cancer Center

Paganini Biopharma, Inc.

Jonathan Braun

Christopher L Sutton

Lynn K Gordon

Madhuri Wadehra

Stephan R Targan

Anna M Wu

Robert H Schiestl

Bo Wei

Kathy A Kelly

Aya M Westbrook

Kaori Shimazaki Dadgostar

Offer Cohavy

Kathleen A Kelly

Ramune Reliene

Kaori Shimazaki

James Borneman

Laura L Presley

Mitsuko L Yamamoto

Robert Soslow

Lee A Goodglick

David Telander

Lin Lin

Sathima Natarajan

Madhuri Wadehra-Dhawan

Kaori Shimizaki

Madhuri Wadegra-Dhawan

Ashley Forbes

Shawn A Morales

Gary S Lazar

David G Telander

Shawn Morales

Provided herein are novel anti-EMP2 antibodies useful for the treatment and diagnosis of cancers that express or overexpress EMP2. In one aspect, provided herein is an isolated antibody that binds to Epithelial Membrane Protein 2 (EMP2), that includes heavy chain variable region and a light chain variable region. The heavy chain variable region includes three heavy chain complementary determining regions (HCDRs) and the light chain variable region includes three light chain variable regions (LCDRs). In some embodiments, the sequence of HCDR1 is SEQ ID NO: 11, the sequence of HCDR2 is SEQ ID NO: 12, the sequence of HCDR3 is SEQ ID NO: 13, the sequence of LCDR1 is SEQ ID NO:14, the sequence of LCDR2 is SEQ ID NO: 15, and the sequence of LCDR3 is SEQ ID NO: 16.

Antibodies for the treatment of cancers

Inoculation of ATM-deficient mice with probiotic microorganisms, such as, changed immune parameters, decreased a marker of DNA damage and increased the lifespan of the mice. Compositions and methods described herein are useful for the treatment and prevention of Ataxia telangiectasia and other cancer-prone disease, such as p53 deficiency-associated cancers. Compositions and methods of the present invention are also useful for treating and preventing radiation-induced toxicity to normal tissue in a subject being exposed to radiation. Compositions and methods of the invention can increase lifespans in a simple, non-invasive manner.

Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life

NK cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are described herein.

Diagnostic tools for response to 6-thiopurine therapy

Inoculation of ATM-deficient mice with probiotic microorganisms, such as, changed immune parameters, decreased a marker of DNA damage and increased the lifespan of the mice. Compositions and methods described herein are useful for the treatment and prevention of Ataxia telangiectasia and other cancer-prone diseases, such as p53 deficiency-associated cancers. Compositions and methods of the present invention are also useful for treating and preventing radiation-induced toxicity to normal tissue in a subject being exposed to radiation. Compositions and methods of the invention can increase lifespan in a simple, non-invasive manner.

The present invention provides methods and compositions useful in the treatment or prevention ofinfections and cancer. The methods and compositions inhibit the entry ofinto a host cell expressing EMP2 by interfering with the interaction between theand EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.

Antibodies which bind to epithelial membrane protein 2 (EMP2)

Methods of preventing retinal detachment associated with proliferative vitreoretinopathy are provided by administering agents which antagonize the activity or function of EMP2 to subjects at risk of the detachment.

Epithelial membrane protein-2 (EMP2) and proliferative vitroretinopathy (PVR)

The present invention discloses methods of using epithelial membrane protein 2 (EMP2) as a biomarker for stratification of endometrial premalignancy, diagnosing, staging and imaging of endometrial neoplasia. Further, methods for identifying pharmaceutical/therapeutic modalities are described, including compositions which modulate glycolipid-enriched lipid raft microdomains (GEMs).

Methods for diagnosis and treatment of endometrial cancer

Methods of treating cancer by administering EMP2 antibodies

The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of DNA damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation. The method can be adapted for quantitatively monitoring the efficacy of treatment of inflammatory disease in a subject. Markers of DNA damage include single- and/or double-stranded breaks in leukocytes, oxidative DNA damage in leukocytes, or a marker of nitric oxide oxidative activity (protein nitrosylation in leukocytes). The inflammatory disease can be inflammatory bowel disease (ulcerative colitis or Crohn's disease). The invention may also be used for detection of other types of inflammatory disease, such as non-immune intestinal inflammatory disease (diverticulitis, pseudomembranous colitis), autoimmune diseases (rheumatoid arthritis, lupus, multiple sclerosis, psoriasis, uveitis, vasculitis), or non-immune lung diseases (asthma, chronic obstructive lung disease, and interstitial pneumonitis). This unexpected discovery of markers of genotoxicity present in circulating leukocytes enables detection of inflammation occurring at a localized site with a relatively simple and minimally invasive assay using peripheral blood.

Genotoxicity as a biomarker for inflammation

EMP2 antibodies and methods of use thereof for causing regression of a solid tumor or symptoms thereof

EMP2 antibodies and methods of use thereof causing regression of a solid tumor or symptoms thereof

The present invention provides methods and compositions useful in the treatment or prevention ofinfections. The methods and compositions inhibit the entry ofinto a host cell expressing EMP2 by interfering with the interaction between theand EMP2. The compositions include EMP2 nucleic acids and polypeptides as well as anti-EMP2 antibodies.

Prevention of chlamydia infection using SIRNA

EMP2 antibodies and their therapeutic uses

Growing community of inventors

Tarzana, CA, United States of America

Jonathan Braun